Evaluation of the severity of chylothorax and the localization of the leakage site of chyle by three-dimensional thoracic duct scintigraphy

Evaluation of the severity of chylothorax and the localization of the leakage site of chyle by three-dimensional thoracic duct scintigraphy - Validation of three-dimensional thoracic duct scintigraphy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009782

Enrollment

Registered

2013-03-14

Start date

2013-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chylothorax

Interventions

Three-dimensitonal thoracic duct scintigraphy using orally-administered 15-(4-iodophenyl)-3(R,S)-methylpentadecanoic acid (BMIPP)and single Photon Emission Tomography (SPECT)/CT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Diagnosis of chylothorax by thoracentesis regardless of a history of surgery 2 Fair ggeneral condition (PS below 2) No history of heart disease. 3 There is written consent of the patient.

Exclusion criteria

Exclusion criteria: 1 Under 20 year old 2 Lactating or pregnant women 3 With dysphagia 4 Previous participation of clinical trials etc.

Design outcomes

Primary

Measure	Time frame
To correlate the parameters of 3D-thoracic duct scintigraphy and subsequently-increased amount of chylous pleural effusion.	—

Countries

Japan

Contacts

Public ContactKentaro Takanami

Tohoku University Hospital Department of Radiology

takanami@rad.med.tohoku.ac.jp022-717-7312

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026